Janssen Pharmaceutical Companies of Johnson & Johnson officially opened its state-of-the-art vaccines launch facility in Leiden, the Netherlands. The new facility represents a significant investment by the company in novel vaccines development, global health and security, and pandemic preparedness efforts. In addition, the facility features innovative technological and manufacturing platforms to support the large-scale production of vaccines for clinical trials and global launch.
Janssen’s launch facility is the latest example of the company’s leadership in pharmaceutical R&D in the Netherlands. The company will utilize a number of cutting-edge research and development (R&D) platforms at the vaccines launch facility, including Janssen’s proprietary AdVac® viral vector vaccines technology and the company’s PER.C6® manufacturing platform.
“This new center represents a significant commitment by Johnson & Johnson in our mission to change the trajectory of human health,” said Johan Van Hoof, M.D., Global Therapeutic Area Head IDV, Vaccines, Janssen Pharmaceuticals R&D and Managing Director, Janssen Vaccines & Prevention B.V.
By investing locally, we hope to protect globally by ensuring that innovative and effective vaccines become available to the people that need them wherever they may live.
Europe’s Leading Hub for R&D Innovation
The Netherlands’ world-class research institutes, supportive R&D tax credits and strategic partnerships between science, industry and government, make it a renowned hub for R&D. Furthermore, Holland is home to R&D operations of major companies like Philips, IBM and MSD. Janssen will utilize Holland’s unmatched technology infrastructure, multilingual workforce and innovative ecosystem to improve global health and create new vaccines.